Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 30, 2025 -- For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless of treatment employed, according to a study published online April 23 in Blood Advances.
Ahmad Y. Abuhelwa, Ph.D., from the University of Sharjah in the United Arab Emirates, and colleagues examined the association of statin use with survival and adverse event outcomes in patients with CLL/SLL initiating contemporary treatment regimens, including ibrutinib, using individual participant data from four randomized trials.
Overall, 29 percent of 1,467 patients were using statins. The researchers found a significant association for statin use with improved overall survival, progression-free survival, and cancer-specific survival (adjusted hazard ratios, 0.55, 0.73, and 0.39, respectively). The findings were consistent for those treated with ibrutinib and nonibrutinib and for CLL versus SLL diagnosis. There was no significant association observed between statin use and grade ≥3 adverse effects.
"These findings don't allow us to say for certain that statins directly improve cancer outcomes," Abuhelwa said in a statement. "However, the fact that this association remained strong even after accounting for multiple factors makes it an important area for future research."
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Disparities Identified in Leukemia Incidence, Mortality in Florida
TUESDAY, March 25, 2025 -- There are racial and geographic disparities in the incidence of and mortality from adult leukemia in Florida, where the incidence of leukemia is the...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing...
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
FRIDAY, Feb. 21, 2025 -- For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax with or without obinutuzumab...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.